Drugs Made In America Acquisition II advanced its financing plans with Alpha Multi Family Office, entering a definitive agreement for a contemplated $1.4 million convertible notes financing and issuing a new $300,000 interim convertible note. The definitive agreement formalizes the structure to fund the SPAC’s transaction needs, while the interim note provides near-term liquidity. The interim note carries no interest, matures in nine months, and may convert at a 35% discount to market upon the completion of the company’s initial business combination. Proceeds will support accounting, audit, and other combination-related expenses.
Agreement 1: Drugs Made In America Acquisition II Enters Definitive Agreement for $1.4 Million Convertible Notes
- Agreement type: Definitive Investment and Sponsor Transition Agreement for $1.4 million Convertible Notes Financing
- Counterparty: Alpha Multi Family Office
- Signed / Effective: Mar 24 2026 / Mar 24 2026
- Reason: Support SPAC transaction costs and liquidity
Agreement 2: Drugs Made In America Acquisition II Issues $300,000 Interim Convertible Note With 35% Discount
- Agreement type: Interim Convertible Note
- Counterparty: Alpha Multi Family Office
- Signed / Effective: Mar 30 2026 / Mar 30 2026
- Duration / Termination: 9 months unless earlier converted
- Reason: Finance audit and business combination expenses
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.